Overview

Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

Status:
NOT_YET_RECRUITING
Trial end date:
2033-09-30
Target enrollment:
Participant gender:
Summary
This clinical research study is to learn if CD70.CAR NK cell therapy can help to control early relapsed or primary refractory DLBCL and cHL.
Phase:
PHASE2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Bellicum Pharmaceuticals
Treatments:
AP 1903 reagent
Cyclophosphamide
fludarabine
fludarabine phosphate